How GLP-1 actually works

Swallow a dose of glucose and your pancreas releases far more insulin than if the same glucose were dripped straight into a vein. The difference — the incretin effect — is the gut signaling the pancreas that food has arrived, before blood sugar has even fully risen. The chemical carrying most of that message is GLP-1, glucagon-like peptide-1, released from intestinal L-cells after a meal.

In type 2 diabetes this incretin effect is blunted. That single observation — a gut-to-pancreas signal that weakens in disease — is what turned GLP-1 from a piece of physiology into one of the most consequential drug targets in modern medicine.

GLP-1 binds the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor on the pancreatic beta cell. The receptor couples to Gαs, which switches on adenylyl cyclase, which raises the cell’s level of the second messenger cAMP. Elevated cAMP acts through two effectors — protein kinase A (PKA) and Epac2 — and the net result is to potentiate insulin secretion.

Nothing in that cascade is exotic; it is textbook GPCR signaling. What makes GLP-1 remarkable is not the machinery but its condition.

The cAMP arm does not, by itself, fling insulin granules out of the cell. Exocytosis is triggered by the beta cell’s own glucose sensing: glucose metabolism raises ATP, ATP-sensitive potassium (K_ATP) channels close, the membrane depolarizes, voltage-gated calcium channels open, and the calcium influx drives granule release. GLP-1’s cAMP/PKA/Epac2 signal amplifies that calcium-dependent step — it turns up the gain on a process the glucose signal has already started.

GLP-1R signaling reaches well past insulin release:

• Glucagon suppression. It restrains glucagon release from pancreatic alpha cells — again glucose-dependently — reducing hepatic glucose output.
• Slowed gastric emptying. It delays the stomach's release of contents, blunting the post-meal glucose spike and prolonging fullness.
• Central satiety. GLP-1 receptors in the hypothalamus and area postrema reduce food intake — a major contributor to the weight effects seen with receptor agonists.
• Beta-cell trophic effects. In rodents, GLP-1R signaling supports beta-cell proliferation and survival; how far this translates to humans is less established.

Native GLP-1 is almost useless as a drug in its raw form: its circulating half-life is roughly one to two minutes. The enzyme DPP-4 clips its N-terminus (at the His7–Ala8 bond) into an inactive fragment within minutes, and the kidney clears the rest. Pharmacology solves this two ways:

• Block the enzyme. DPP-4 inhibitors slow the degradation of the GLP-1 (and GIP) your own gut already makes, raising endogenous incretin tone.
• Build a resistant agonist. Exendin-4 — a peptide from Gila monster venom — is naturally DPP-4-resistant. Attaching a fatty-acid chain (acylation) lets engineered analogs bind albumin and evade clearance, stretching the half-life from minutes to days.

That half-life engineering is exactly what the dosing calculator makes tangible: push a 1.5-minute half-life out to several days and the whole accumulation and steady-state picture changes.

GLP-1 is no longer pursued alone. Because the GIP and glucagon receptors add complementary metabolic effects, engineered peptides now deliberately hit more than one receptor at once: GLP-1/GIP dual agonists, and GLP-1/GIP/glucagon tri-agonists in trials. The logic is additive physiology — recruiting several arms of the metabolic system — rather than simply a bigger dose of one signal.

Established: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central appetite reduction through this pathway, with substantial weight and glycemic effects and cardiovascular and renal outcome signals in large trials.

Open: the precise split between gastric, central, and other mechanisms behind weight loss; long-horizon effects; whether GIP agonism or antagonism is preferable; and muscle preservation during rapid weight loss — the question driving interest in adjacent myostatin/activin pathways.